Pfizer Inc. (NYSE:PFE) Banks on Expanding Drug Mandate, Cost Reduction

Boston, MA, 11/21/2013 (wallstreetpr) – Pfizer Inc. (NYSE:PFE) is the world’s largest drug maker with a lot of product portfolio and patents. The drug company also has a lot of medical solutions in the pipeline which it banks to improve its financial situation.  Like most other businesses in the health care sector, Pfizer Inc. (NYSE:PFE) […]

Oncology Remains Pfizer Inc. (NYSE:PFE)’s Strongest Unit

Boston, MA 11/04/2013 (wallstreetpr) – The pharmaceutical giant Pfizer Inc. (NYSE:PFE) released its Q3 data last week, being among the last few in the industry to round off the health care stocks picture after other players having reported earlier. PFE Q3 results topped analysts’ estimates due to its intensive restructuring and cost reduction measures. The company reported […]

Pfizer Inc (NYSE:PFE) discloses their third quarter results

Recently, Pfizer Inc (NYSE:PFE) disclosed their third quarter results which provided results and reports related to third quarter reports and performance of the company. Moreover, forward looking statements were discussed at the time of disclosure of the third quarter report. There were also various things which were discussed in Pfizer’s 2012 annual report on the […]

Pfizer Inc. (NYSE:PFE) again joins hand in pain killer partnership with the Austin firm

There has been a confirmation received from an Austin based Pain Therapeutics Inc that Pfizer Inc. (NYSE:PFE) plans to continue their working with the organization in the development program for the pain killer “Remoxy”. About the pain killer Pain killer “Remoxy” has been rejected twice by the United States of America Food and Drug Administration […]

Pfizer Inc. (NYSE:PFE) – Strong Portfolio Aid To Growth

Boston, MA 10/22/2013 (wallstreetpr) – Pfizer Inc. (NYSE:PFE), is a research based biopharmaceutical company. They operate in different segments. The company’s diversified portfolio includes animal, human, biologic, vaccine, and small molecule, as well as consumer healthcare and nutritional products. Pfizer’s shareholders have witnessed an appreciation in the share’s value by around 11% which signifies the […]

Civil Lawsuits Against Pfizer Inc. (NYSE:PFE) Moved To The Federal Docket

Boston, MA 10/21/2013 (wallstreetpr) – Separate civil lawsuits that were filed against Pfizer Inc. (NYSE:PFE) in the McDowell County civil court in West Virginia have now been moved to the federal docket in the US District Court for the Southern District of West Virginia and will now be handled there. There were multiple plaintiffs involved in some […]

Pfizer Inc. (NYSE:PFE) Reported Unsatisfactory Results Of Drug For Psoriasis Treatment

Boston, MA 10/18/2013 (wallstreetpr) – A drug tofacitinib which the drug maker Pfizer Inc. (NYSE:PFE) had earlier come up with to treat psoriasis is now seen to demonstrate mixed results in the trials. The company reported that the drug has shown non-inferiority compared to Enbrel in treating psoriasis in adults who were suffering moderately or severely from […]

Pfizer Inc. (NYSE:PFE) Funds Study On Expenditure On Cancer Drugs

Boston, MA 10/15/2013 (wallstreetpr) – According to a research, 126 billion Euros ($171 billion) were spent on cancer drugs in the year 2009. This was established by researchers based in United Kingdom. The research might be helpful to the cancer research officers who might find themselves better equipped with information on cancer and in fighting the […]

What It Means That Pfizer Inc.’s (NYSE:PFE) Ambitious Duavee Menopause Drug Now Gets FDA Approval

Boston, MA 10/07/2013 (wallstreetpr) – The FDA approval of Duavee, a menopause drug from Pfizer Inc. (NYSE:PFE) makes a lot of business sense for this global biopharmaceutical company and its investors. While there are already other menopause drugs in the market, PFE’s Duavee is a different one; it is devoid of the usual side effects […]

Pfizer, Inc. (NYSE:PFE) to Close West Ryde Plant of Sydney by 2015

Boston, MA 10/02/2013 (wallstreetpr) – Pfizer, Inc.’s (NYSE:PFE) contributions in the field of medical research and healthcare industry can never be ignored. It is a renowned biopharmaceutical company and has marked its operating presence in all across the globe. The company since past few years is however concentrating on reducing costs and in the process […]

Stock Guidance and Strategies – Pfizer Inc. (NYSE:PFE)

Boston, MA 07/23/2013 (wallstreetpr) – Despite increase in profits by 53% and revenues over 6% from emerging markets during the first quarter, Pfizer Inc. (NYSE:PFE) has cut its full-year diluted EPS guidance from $1.50-$1.65 to $1.44-$1.59. Stiff competition, loss of exclusivity on its bestsellers, slower than expected sales of new products and currency fluctuations with regards […]